Endothelial cells play an important role in the process of coagulation and the function of platelets. We have previously reported that 20-hydroxyeicosatetraenoic acid (20-HETE), a metabolite of arachidonic acid, increased platelet aggregation and induced hemostasis. The purpose of the present study is to investigate whether 20-HETE-mediated endothelial activation has effect on the coagulation and platelet aggregation. C57Bl/6 mice were treated with PBS or 20-HETE (20 g/kg) for 2 h, and then we performed a carotid artery or femoral artery thrombosis model by FeCl 3. Detection of blood flow indicated that 20-HETE pretreatment accelerated formation of thrombus in both common carotid artery and femoral artery. In vitro, the secretion and expression of von Willebrand factor (vWF) in cultured human umbilical vein endothelial cells (HUVECs) with 20-HETE stimulation were increased, subsequently. The protein level of vWF in HUVECs was decreased at 1 h but increased with prolonged treatment with 20-HETE (Ͼ4 h). In contrast, vWF in the culture medium was increased under administration of 20-HETE at 1 h. As a result, adhesion of platelets on HUVECs was significantly increased by 20-HETE. In HUVECs, the extracellular signal-regulated kinase (ERK) pathway was activated by 20-HETE in a dose-dependent manner, and the inhibitors of ERK and L-type Ca 2ϩ channel blocked the release of vWF mediated by 20-HETE. In conclusion, 20-HETE instigates endothelial activation and induces the expression and secretion of vWF via the activation of ERK and calcium channel and therefore triggers thrombosis.
20-HYDROEXYEICOSATETRAEONIC acid (20-HETE) is derived from arachidonic acid metabolized by CYP4A and -4F families in humans. 20-HETE plays vital roles in regulating renal functions and arterial pressure (41, 43) by mediating the response of arteries to angiotensin II, endothelin-1, and nitric oxide (NO) (3, 4, 20) . Moreover, recent studies have indicated that 20-HETE can mediate endothelial activation and dysfunction by inducing endothelial NO synthase (eNOS) uncoupling or activating the MEK/extracellular signal-regulated kinase (MEK/ ERK) pathway (1, 4, 19, 39) . 20-HETE is involved in various diseases such as cerebrovascular disease and coronary heart disease (26) . We and collaborators have found that increased level of 20-HETE in plasma was associated with significantly shorter tail bleeding time in a murine model, and 20-HETE dose dependently increased rat platelet aggregation in vitro (22) . These results suggest that 20-HETE may accelerate blood coagulation. However, the role of 20-HETE in hemostasis is still unclear.
Endothelium participates extensively in the process of hemostasis, which maintains the balance of coagulation and anticoagulation via releasing factors or providing requisite receptors. Thrombomodulin and the tissue factor pathway inhibitor are predominantly expressed on the surface of endothelial cells and perform anticoagulant effect via controlling the coagulation cascade (7, 40) . Fibrinolysis is a key step of hemostasis during which endothelial cells are highly involved through expression of tissue-type plasminogen activator (t-PA), urokinase-type plasminogen activator (u-PA), u-PA receptor, and plasminogen activator inhibitor-1 (PAI-1) (2, 6, 25, 37) . Moreover, endothelial cells regulate platelet activation and aggregation by releasing NO, prostacyclin (PGI 2 ), and von Willebrand factor (vWF) (10, 12, 14) . vWF is the major protein of the Weibel Palade body and is only synthesized in endothelial cells and megakaryocytes. Upon stimulation of vasoactive agents such as histamine and thrombin, Weibel Palade bodies in endothelial cells (ECs) are activated and release vWF within minutes (31, 32, 36) . vWF is a large plasma glycoprotein mediating platelets adhesion. Decreased level or dysfunction of vWF causes von Willebrand disease in humans (35) . vWF also plays an important role in regulating inflammation and angiogenesis (34) .
Whereas 20-HETE is involved in both EC function and blood coagulation, we still have no proof of 20-HETE regulating coagulation via EC activation, and the actual mechanisms also need further investigation. Therefore, we hypothesized that 20-HETE may promote thrombosis through regulating vWF in ECs. In other words, 20-HETE may mediate EC activation by increasing vWF release and expression, thereby inducing platelet adhesion and accelerating thrombus formation.
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Materials.
Human umbilical vein endothelial cells (HUVECs) were isolated and cultured as described (9) . 20-HETE was obtained from Cayman Chemical (Ann Arbor, MI). Antibodies against ␤-actin, phospho-ERK1/2 (p-ERK1/2), total ERK2, and vWF were purchased from Santa Cruz (Santa Cruz, CA). FR-180204 was purchased from Santa Cruz. All other reagents were acquired from Sigma (St. Louis, MI), unless otherwise indicated.
Animals. C57Bl/6 wild-type mice were obtained from the Jackson Laboratory (Bar Harbor, ME) and were 8 to 12 wk old. Mice were housed in temperature-controlled cages under a 12:12-h light-dark cycle with free access to water and regular rodent diets, as described (23 Ferric chloride thrombus model. C57Bl/6 mice were anesthetized. The carotid artery and the femoral artery were exposed. The ferric chloride thrombus model was created as previously reported (27) using 2.5% of FeCl 3 for 3 min. Blood flow of the carotid artery was monitored every 5 min by removal of FeCl3-saturated filter paper with use of Transonic TS420 and Chart5 software (Transonic). Perfusion rate of the femoral artery was determined by use of the Laser-Doppler Perfusion Imager (PeriScan PIM3; Perimed).
Cell culture. HUVECs were cultured with EC basal medium supplemented with EGM SingleQuots from LONZA (Walkersville, MD), 5% fetal bovine serum, penicillin (100 U/ml), and streptomycin (100 g/ml) as described (15) . Cells between passages 3 and 8 were used in all experiments. Cells were incubated at a 37°C in a humidified atmosphere of 5% CO 2 and grown to 70 -80% confluence before treatment.
Platelet adhesion. Venous blood was obtained from male SpragueDawley rats. Preparation of platelet-rich plasma (PRP), platelet-poor plasma (PPP), and washed platelets was as described (18) . Platelets were labeled with fluorescence dye [2=,7=-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein (BCECF)]. HUVECs were cultured and placed in serum-free medium for 2 h and then treated with vehicle or different concentrations of 20-HETE for 2 h. The medium was discarded or remained, and PRP or PPP were cocultured with cells for 1 h; fluorescence was detected by use of a fluorescent plate reader.
Western blot analysis. Western blotting was performed as described previously (15) . The intensity of bands was quantified by densitometry (AlphaEaseFC; Alpha Innotech).
Real-time PCR analysis. Total mRNA was isolated from HUVECs by use of the RNeasy Mini kit (Qiagen, Limburg, Netherlands). Quantification was as previously described (15) . ␤-Actin was an endogenous control. The nucleotide sequences for primers are as in Table 1 .
Statistical analysis. Quantitative data are expressed as means Ϯ SE. Differences between groups were analyzed by one-way repeatedmeasures Bonferroni ANOVA or Student's t-test. P Ͻ 0.05 was considered statistically significant. For nonquantitative data, results are representative of at least three independent experiments. 
RESULTS
20-HETE had a prothrombosis effect in the FeCl
20-HETE increased the adhesion of platelets to ECs.
Adhesion of platelets to activated ECs is the initial step in thrombus formation, atherosclerosis, and other vascular lesions. 20-HETE could activate ECs (4, 38) via inducing eNOS uncoupling, but its function on platelet adhesion was unknown. The finding of increased thrombosis in the FeCl 3 murine model under 20-HETE treatment led us to hypothesize that 20-HETE may play a role in controlling the adhesion of platelets to ECs.
To investigate the function of 20-HETE on activated ECs, HUVECs were treated with 20-HETE for 2 h and incubated with platelets labeled with fluorescence dye (BCECF) for another hour. Platelet adhesion to HUVECs was increased to 1.5-fold with 20-HETE treatment ( Fig. 2A) , suggesting that 20-HETE could promote platelets adhesion to activated ECs and may have a potential function in blood coagulation.
To exclude the direct effect of 20-HETE on platelets, HUVECs were treated with 20-HETE for 2 h, and then culture medium was removed to examine platelet adhesion. Preincubation of 20-HETE increased the adhesion to 1.3-fold (Fig.  2B) . Moreover, after treatment of HUVECs with 20-HETE for 2 h, PPP was incubated with HUVECs to observe fibrin formation. Similarly, culture medium was changed or not after treatment for 2 h. The wet weight of fibrin was increased by 41 or 50% of control treatment (Fig. 2, C and D) in medium with or without 20-HETE, respectively. These results suggest EC activation mediated by 20-HETE could induce platelets adhesion and fibrin formation at the same time.
20-HETE regulated EC gene expression in hemostasis.
ECs play vital roles in hemostasis and express a series of factors involved in platelet adhesion and aggregation, coagulation cascade, and fibrinolysis. To explore the function of 20-HETE in these aspects, HUVECs were first starved overnight and then treated with 20-HETE for 2 h. Cells were harvested, and related gene expression was detected. 20-HETE had little effect on genes involved in fibrinolysis, represented by t-PA, u-PA, and PAI-1 expression (Fig. 3A) . Correspondingly, with increased platelet adhesion, 20-HETE treatment significantly increased the expression of vWF and platelet/endothelial cell adhesion molecule (PECAM)-1 but had no effect on the PGI 2 synthesis enzyme PTGIS (Fig. 3B) .
To further confirm the effect of 20-HETE in vivo, we detected these markers of coagulation and fibrinolysis in the plasma of 20-HETE or PBS-injected mice. As shown in Fig.  3C , 20-HETE treatment or simulation of FeCl 3 did not affect the secretion of fibrinolysis-related markers, which is in accordance with in vitro results. Furthermore, we found 20-HETE could increase FeCl 3 -induced vWF and PECAM-1 release, which indicated that 20-HETE activated ECs and enhanced FeCl 3 -induced endothelial injury. As shown in Fig. 3D , vWF secretion in the acute FeCl 3 -induced thrombosis model was remarkably increased after 20-HETE injection. It would be a conviction of our in vitro result (Fig. 3B) . the level of vWF expression was significantly decreased to 40% of the control in a short time (1 h) but increased after 4 h with 20-HETE treatment (Fig. 4A) . Because ECs store vWF in Weibel Palade bodies and exhibit both stimulated secretion and constitutive secretion (4, 28), we determined vWF content in culture medium after treatment with 20-HETE for 2 h. Compared with control treatment, 20-HETE increased vWF content in the medium to 130% (Fig. 4B) . Consistently, 20-HETE treatment caused cellular protein levels of vWF to decrease in the short term (1 h, Fig. 4C ) and increase with prolonged time (24 h, Fig. 4D ) in a dose-dependent manner. The discrepancy of our short-term results with prolonged 20-HETE treatment suggests that 20-HETE upregulated vWF expression at the transcriptional level, whereas induction of vWF secretion occurred immediately.
20-HETE increased the expression and secretion of vWF.
Chelation of exogenous calcium or inhibition of ERK abolished 20-HETE-induced vWF secretion.
The ERK1/2 pathway mediates 20-HETE signaling and EC dysfunction (5, 17) . To investigate the relationship between the 20-HETE-mediated ERK1/2 pathway and vWF regulation, HUVECs were treated with 20-HETE for different times. The activation of the ERK1/2 pathway was determined by ERK1/2 phosphorylation (p-ERK1/2). p-ERK1/2 level was increased significantly with 20-HETE at 1, 2, 4, and 8 h (Fig. 5A) . Furthermore, activation of ERK by 20-HETE was as early as 30 min (Fig. 5B) . Consistently, the phosphorylation of ERK1/2 was also increased in aortas of 20-HETE-treated mice compared with control mice (Fig. 5C ). To investigate whether vWF release was involved in ERK1/2 activation by 20-HETE, we used a specific inhibitor of ERK1/2 (FR-180204, 10 M) (29) . FR-180204 reversed the 20-HETE-mediated decrease of vWF at the protein level and increased the vWF basal protein level (Fig. 5D) . In contrast, 20-HETE-induced vWF secretion to culture medium was reduced with FR-180204 (Fig. 5E) ; therefore, ERK activation is important in 20-HETE-triggered vWF secretion. Furthermore, increase of intracellular calcium is a central event in vWF release from Weibel Palade bodies (24) . We investigated the effect of calcium chelation on 20-HETEinduced vWF release. EDTA, a calcium chelator, abolished the secretion of vWF (Fig. 5F ), suggesting that calcium was required for 20-HETE-induced vWF secretion in ECs. L-type Ca 2ϩ channel was known to mediate the effect of 20-HETE in ECs (20); we found that verapamil, an inhibitor of L-type Ca 2ϩ channel blocker, could abolish the effect of 20-HETE on vWF release (Fig. 5G) . These results indicated that L-type Ca 2ϩ channel-mediated Ca 2ϩ influx was important for vWF regulation.
To investigate the prolonged effect of ERK-mediated vWF induction, we pretreated HUVECs with FR-180204 and incubated them with 20-HETE for 24 h. Compared with the control, FR-180204 did not affect the vWF basal protein level in HUVECs but lowered the 20-HETE-induced vWF protein level (Fig. 5H) . Therefore, ERK1/2 activation plays a key role in 20-HETE-mediated vWF upregulation in ECs.
DISCUSSION
Our previous work showed that the cyclooxygenase-2 (COX-2) inhibitor induced 20-HETE accumulation in mice, which was associated with coagulation and ADP-induced platelet aggregation (22) . This finding provides an insight into the clinical side effects of the COX-2 inhibitor and indicates that 20-HETE might play an important role in regulating coagulation. In the current study, we investigated whether 20-HETE is involved in coagulation by activating ECs. We aimed to elucidate the procoagulation effect of 20-HETE in ECs and clarify a new regulatory mechanism of vWF.
The FeCl 3 -induced thrombus model is widely used to study thrombogenesis in vivo with the mechanism of inducing endothelial injury and platelet aggregation (8) . We conducted a thrombus model in the right common carotid artery and femoral artery of mice for a short time (30 min) and found that injection of 20-HETE could significantly aggravate thrombus formation, which effectively showed the procoagulant effect of 20-HETE.
To uncover the underlying mechanism in this process, we studied the function of 20-HETE in the endothelium. The endothelium is extensively involved in hemostasis, mostly by activating platelets, coagulation cascade, and fibrinolysis. In cultured HUVECs, 20-HETE pretreatment significantly increased the adhesion of platelets to ECs (Fig. 2A) , an initial Real-time PCR analyses of the mRNA expression of genes were presented. Data are means Ϯ SE (n ϭ 3). *P Ͻ 0.05 and **P Ͻ 0.01 vs. control cells. C and D: mice were injected with 20-HETE (20 g/kg) for 2 h, and a FeCl3 model was performed on the femoral artery for 30 min. Plasma was obtained immediately after operation, and factors were determined via ELISA kits. t-PA, tissue-type plasminogen activator; u-PA, urokinase-type plasminogen activator; PAI-1, plasminogen activator inhibitor-1; vWF, von Willebrand factor; PECAM-1, platelet/endothelial cell adhesion molecule. Data are means Ϯ SE (n ϭ 10). **P Ͻ 0.01 and ***P Ͻ 0.001.
step of FeCl 3 -induced thrombus formation (8) . Previous studies by Hill et al. demonstrated that 20-HETE was an inhibitor of arachidonic acid-and thromboxane-induced platelet aggregation by competitively blocking the thromboxane/endoperoxide receptor (16, 30) . To distinguish the effect of 20-HETE on ECs and platelets, we refreshed medium before platelet incubation (Fig. 2B) . Our findings suggested that the procoagulant effect of 20-HETE on ECs was dominant during coagulation, which was also supported by increased fibrin formation in HUVECs preincubated with 20-HETE (Fig. 2, C and D) . In addition, the mRNA levels of EC activation markers PECAM-1 and vWF were increased by 20-HETE, whereas fibrinolysis-related genes such as t-PA, u-PA, and PAI-1 or platelet activation-related genes such as PTGIS or eNOS remained unaltered (Fig. 3 ). Consistent with the mRNA level, vWF protein expression was increased with long-term 20-HETE stimulation (Fig. 4) . However, the cytoplasm vWF protein level was reduced with short-term 20-HETE treatment, but the concentration of vWF in medium was increased (Fig.  4A) . Our results provide evidence that regulation of vWF mediated by 20-HETE included both transcriptional regulation and protein secretion. vWF is a vital factor for the balance between coagulation and bleeding by stabilizing blood coagulation factor VIII and recruiting platelets to sites of vascular injury (42) . High plasma level of vWF is associated with multiple cardiovascular diseases (33) , and vWF participates in the activation and adhesion of platelets (13, 21) , which explained the increased platelet adhesion to ECs and the formation of thrombus in our animal model. Our findings indicate that 20-HETE plays a procoagulation role by regulating vWF, and the latter may be a factor exerting the side effects of the COX-2 inhibitor. Western blot analysis of vWF and ␤-actin as endogenous control protein levels was presented. The pattern below is the quantification graph (n ϭ 3; *P Ͻ 0.05 and ***P Ͻ 0.001 vs. 0 h). B: HUVECs were treated with 20-HETE (100 nM) for 1 h, and medium was collected. ELISA determination of release of vWF to the medium was presented (n ϭ 3; ***P Ͻ 0.001 vs. control). C: cultured HUVECs were treated with 20-HETE (1 h) at different doses, and the result below is the quantification graph (n ϭ 3; *P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001 vs. 0 nM) D: cultured HUVECs were treated with 20-HETE (24 h) at different doses, and the result below is the quantification graph (n ϭ 3; *P Ͻ 0.05 and ***P Ͻ 0.001 vs. 0 nM).
Many factors may contribute to the procoagulation effect of 20-HETE. We showed that 20-HETE treatment upregulated PECAM-1 and Ptgis in vivo. However, vWF secretion was the most sensitive and consistent marker detected both in the plasma of mice and in the culture supernatant of ECs after 20-HETE treatment. Because vWF has been reported to be involved in coagulation and endothelial activation in multiple pathophysiological processes, mechanisms of 20-HETE regulating vWF secretion and expression were further investigated. ERK activation mediated by vWF in platelets is essential for platelet activation and aggregation (11) . Besides ERK1/2, activation was reported to induce exocytosis of Weibel Palade bodies from ECs (32) . According to our results, 20-HETE could mediate quick and sustained phosphorylation of ERK1/2 and increase vWF release. Also, ERK inhibition significantly blocked the 20-HETE-mediated increase of vWF in ECs ( 5H), which suggests that the ERK1/2 pathway plays an important role in 20-HETE-mediated EC activation. Moreover, 20-HETE can reduce the open state of Ca 2ϩ -activated K ϩ channels and increase the cellular calcium level, which could trigger vWF release from Weibel Palade bodies (24, 30) . Consistent with previous studies, calcium chelation by EDTA significantly inhibited the release of vWF induced by 20-HETE. Both inhibiting the influx of Ca 2ϩ and blocking L-type calcium channel could abolish vWF secretion. Thus, 20-HETE performed a procoagulation role by promoting release of vWF at least partially via regulating calcium concentration and activating ERK1/2.
In conclusion, 20-HETE has multiple effects on coagulation, especially on EC function, including advancing platelet adhesion by upregulating vWF expression and secretion. We also found a critical role of ERK pathway activation in 20-HETEregulated vWF actions. Therapeutic inhibition of 20-HETE might be effective in treating COX-2 inhibitor-caused coagulation and could have a beneficial effect in thrombosis and related cardiovascular diseases.
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